Magic is an art in which a magician performs seemingly impossible tricks for entertainment. When it began, people used to associate magic with evil and so the industry faced several hiccups . However, as a result of constant effort of many magicians of that era, people slowly became interested in magic, and came to accept it as a legitimate art in the 18th century. In this post, I will introduce a legend, who was not just a prominent magician, but also an inventor. It…
A patent right is a monopolistic right that is granted only after stringent scrutiny of the patent application. The right is not enjoyed by a patent applicant/patentee unless it is proved beyond reasonable doubt that this proprietorship is well deserved of the invention. Since this grant of patent right affects third parties monumentally, they are given an opportunity to participate and intervene in the grant process by filing oppositions and request for revocations.
An application can be opposed before grant…
India has upgraded Electronic filing facility of patents which was launched 5 years ago. The Indian Patent Office (IPO) first launched the e-filing services for patents in the year 2007 which enabled online filing of new applications for patents. The service is successfully being used by stakeholders. Appreciating the significance, the IPO has further developed the system so as to cover comprehensive e-filing for patents, wherein, in addition to online filing of new applications, subsequent filings have also been integrated. On…
This presentation gives an overview of intellectual property and its various species. It discusses some important types of IP such as patents, copyrights, designs, trademarks, trade secrets and so on, in the light of their relevance to business. Then, the presentation moves onto IP licensing, taking music licensing as an example. The nuances of music licensing are explained during the rest of the presentation.
The talk, unfortunately, not a part of this post, is filled with interesting examples…
The presentation on IP Licensing by Dr. Kalyan Kankanala at IIMB
The presentation on IP Licensing by Dr. Kalyan Kankanala at IIMB, gives an insight into the basics of licensing intellectual property. Beginning with a short introduction to the rights granted by IP, the presentation moves to some types of licenses based on the nature of transaction, field, type etc.
Kalyan then delves into the process of licensing and various steps involved in it, by taking patent licensing as an example.…
A patent is a monopolistic right granted by the government for a specific period of time in return for the disclosure of an invention which is in conformance with the patent laws of a country. The protection for the invention is initiated by making a strategy as to how and when a patent application should be filed and this monopolistic right comes to an end 1 year after the payment of the 20 th year annuity/maintenance fee. The life cycle…
Music licensing means transfer of exclusive or non – exclusive rights to use a piece of music which sometimes may be a complete song, a snippet of a song or an entire album or an entire repertoire for a set period of time, for a fee. Music licensing deals can take several forms, but generally all deals dictate the presence of a licensing fee, an expiration date of the licensing agreement, and terms specifying where and how the licensee can use…
This presentation gives an overview of the patent and introduces students to the patent life cycle. It also delves briefly into justifications for patent protection.
The presentation is available here.
By Dr. Kalyan
Business Value of IP – A Presentation for United Nations Industrial Development Organisation (UNIDO)
This presentation gives an overview of the value of IP for businesses, especially SMEs. The presentation was delivered for the plastics and machine tools industry in Delhi and has specific examples to suit the said industries.
The presentation can be accessed here
By Dr. Kalyan
The Novartis decision of the Indian Supreme Court rejecting patentability of the cancer drug, Imatinib Mesylate in its beta crystalline form (commonly called 'Glivac'), has been commended for its outlook on public interest and access to health. It was in fact an important decision for cancer patients as it removes the last possible hurdle to access the drug at one-tenth of its cost, which was around Rs. 1, 20, 000/- per month. The main issue in the case revolved around…